IP Library Granted Patent US 12,428,408
Granted Patent B2
US 12,428,408 · App. 18/230,332 · Granted Sep 30, 2025

Fused heterocyclic mescaline derivatives

Inventors: Peter J. Facchini (Calgary, CA); Jillian M. Hagel (Calgary, CA); Chang-Chun Ling (Calgary, CA); Ye Cai (Edmonton, CA); David James Press (Calgary, CA); Glynnis Elizabeth Jensen (Calgary, CA); Jessica Bik-Jing Lee (Calgary, CA); Kaveh Matinkhoo (Calgary, CA)
Assignee: Enveric Biosciences Canada Inc.
C07D407/12C07D317/58C07D405/06C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,408
App. No.
18/230,332
Granted
Sep 30, 2025
Kind
B2
Abstract

Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Claims (25)

1. A chemical compound selected from a first chemical compound having chemical formula (I), and a second chemical compound having chemical formula (II):

wherein, in each chemical formula (I) and (II)

R 1 is an optionally substituted alkylene group having 1-3 carbon atoms or a carbonyl group (—C(═O));

X 1 and X 2 are independently selected from an oxygen atom, a sulfur atom, —NH, or an N-alkyl group, and X 3 , X 4 , or X 5 are independently a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an acyl group, an amino group, an N-substituted amino group, an amide group, a substituted amide group, a substituted amido group, a hydroxy group, a cyano group, a carboxy group, a thiol group, or a thioether group, and wherein two or three of X 3 , X 4 , or X 5 are a hydrogen atom;

R 3 is a methyl group, a cyano group, or a hydrogen atom; and

R 4 and R 5 are independently selected from an alkyl group, an alkoxy group, a hydroxyalkyl group, an N-substituted amino group, an alkyl-heteroaryl group wherein the heteroaryl is optionally substituted, or a hydrogen atom, and wherein at least one of R 4 and R 5 is an alkyl-aryl group, wherein the aryl group is substituted by being fused to a 5 or 6 membered heterocyclic ring containing two oxygen atoms, and wherein the aryl group is additionally substituted with a halogen atom, wherein further the amino group (—NR 4 R 5 ) in each of compounds of formula (I) and (II) is optionally protonated to form (—N + HR 4 R 5 ), and chemical formula (I) or (II) further includes a negatively charged anion balancing the positively charged nitrogen atom.

2. A chemical compound according to claim 1 , wherein the amino group (—NR 4 R 5 ) in the compounds of formula (I) and (II) are protonated to form (—N + HR 4 R 5 ), and chemical formula (I) or (II) further includes a negatively charged anion balancing the positively charged nitrogen atom.

3. A chemical compound according to claim 1 , wherein R 1 is an alkylene group having one carbon atom and X 1 and X 2 each are an oxygen atom.

4. A chemical compound according to claim 1 , wherein R 1 is a substituted alkylene group having one carbon atom, wherein the carbon atom is substituted with one or two halogen atoms, optionally fluorine atoms, and X 1 and X 2 each are an oxygen atom.

5. A chemical compound according to claim 1 , wherein R 1 is an alkylene group having two carbons atom and X 1 and X 2 each are an oxygen atom.

6. A chemical compound according to claim 1 , wherein X 3 , X 4 , and X 5 each are a hydrogen atom.

7. A chemical compound according to claim 1 , wherein one of X 3 , X 4 , and X 5 is a halogen or an alkoxy group.

8. A chemical compound according to claim 1 , wherein X 5 is a halogen, optionally a bromine, or an alkoxy group, optionally an (C 1 -C 10 )-alkoxy group, or optionally an (C 1 -C 3 )-alkoxy group, optionally a methoxy group.

9. A chemical compound according to claim 1 , wherein the alkyl group in the alkyl-aryl group is a (C 1 -C 10 ) alkylene group.

10. A chemical compound according to claim 1 , wherein one of the R 4 and R 5 groups is an (C 1 -C 10 )-alkyl group or a (C 1 -C 3 )-alkyl group.

11. A chemical compound according to claim 1 , wherein one of the R 4 and R 5 groups is a (C 3 -C 10 )-cyclo-alkyl group, a (C 3 -C 6 )-cyclo-alkyl group, or a C 4 -cyclo-alkyl group.

12. A chemical compound according to claim 1 , wherein one of the R 4 and R 5 groups is a (C 1 -C 10 )-alkoxy group or a (C 1 -C 3 )-alkoxy group.

13. A chemical compound according to claim 1 , wherein one of the R 4 and R 5 groups is a (C 1 -C 10 )-hydroxyalkyl group or a (C 1 -C 3 )-hydroxyalkyl group.

14. A chemical compound according to claim 1 , wherein one of the R 4 and R 5 groups is a substituted amino group, optionally a (C 1 -C 10 )-alkyl substituted amino group, or optionally a (C 1 -C 3 )-alkyl substituted amino group.

15. A chemical compound according to claim 1 , wherein the chemical compound having formula (I) or formula (II) is selected from the group of compounds selected from: A(VI); A(IX); and A(XI):

wherein in each of compound A(VI), A(IX), and A(XI), optionally, the nitrogen atom of the ethyl amine chain may be protonated and includes a negatively charged anion balancing the positively charged nitrogen atom.

16. A chemical compound according to claim 1 , wherein the compound is at least about 95% (w/w) pure.

17. A pharmaceutical drug formulation comprising an effective amount of the chemical compound of claim 1 together with a pharmaceutically acceptable excipient, diluent, or carrier.

18. A chemical compound according to claim 15 , wherein the compound is at least about 95% (w/w) pure.

19. A pharmaceutical drug formulation comprising an effective amount of the chemical compound of claim 15 together with a pharmaceutically acceptable excipient, diluent, or carrier.

Assignments (17)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: HAGEL, JILLIAN M.; LING, CHANG-CHUN; CAI, YE (CHARLIE); MATINKHOO, KAVEH; PRESS, DAVID JAMES; LEE, JESSICA BIK-JING; JENSEN, GLYNNIS ELIZABETH; FACCHINI, PETER JAMES
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: FACCHINI, PETER JAMES
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: HAGEL, JILLIAN M.
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: LING, CHANG-CHUN
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: CAI, YE (CHARLIE)
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: PRESS, DAVID JAMES
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: JENSEN, GLYNNIS ELIZABETH
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: LEE, JESSICA BIK-JING
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: MATINKHOO, KAVEH
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065648/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: FACCHINI, PETER JAMES
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: HAGEL, JILLIAN M.
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: LING, CHANG-CHUN
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0230 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: CAI, YE (CHARLIE)
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: PRESS, DAVID JAMES
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: JENSEN, GLYNNIS ELIZABETH
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: LEE, JESSICA BIK-JING
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: MATINKHOO, KAVEH
To: ENVERIC BIOSCIENCES CANADA INC.
Reel/Frame 065649/0476 →
Continuity (3)
Provisional Application 63418878 · Oct 24, 2022
Provisional Application 63395492 · Aug 5, 2022
Related Publication 20240116907A1 · Apr 11, 2024
References Cited (66)
US 10435394B2 · Nakano · 2019 [cited by examiner]
WO 2023044574A1 · 2023 [cited by applicant]
Registry No. 801235-02-9, File Registry on STN, entered Dec. 22, 2004. [cited by examiner]
Registry No. 2776951-49-4, File Registry on STN, entered Jun. 23, 2022. [cited by examiner]
Registry No. 1011230-37-7, File Registry on STN, entered Apr. 1, 2008. [cited by examiner]
Registry No. 1301122-06-4, File Registry on STN, entered May 26, 2011. [cited by examiner]
Registy No. 1015671-18-7, File Registry on STN, entered Apr. 18, 2008. [cited by examiner]
Hall and Strange. Brit. J. Pharmacol. 121:731-736, 1997. [cited by applicant]
Mackenzie et al., Eur. J. Pharmacol. 266:79-85, 1994. [cited by applicant]
Cao, D. et al. Science 2022, 375:403-411. [cited by applicant]
Maier et al., J. Pharmacol. Exp. Therap. 330:342-351, 2009. [cited by applicant]
Wurch et al., J. Neurochem. 68: 410-418, 1997. [cited by applicant]
Bryant et al., [Life Sci. 15: 1259-1268, 1996. [cited by applicant]
Shen et al., J. Biol. Chem. 268: 18200-18204, 1993. [cited by applicant]
Pacholczyk et al., Nature 350: 350-354, 1991. [cited by applicant]
Roloff et al., 2013, BMC Neuroscience 14:141-155. [cited by applicant]
Saeger and Olson, 2022, Journal of Neurochemistry 162:109-127. [cited by applicant]
Roloff et al., 2015, PLOS ONE e0118536:1-14. [cited by applicant]
Olson, 2022, Biochemistry 61:127-136. [cited by applicant]
Bogenschutz, M.P. and Johnson M. W. (2016), Prog. in Neuro-Psychopharmacol. & Biol. Psychiatry 64; 250-258. [cited by applicant]
Garcia-Romeu, A.G. et al., (2017), Exp. Clin. Psychopharmacol. Aug. 2016; 24(4): 229-268. [cited by applicant]
McCorvy and Roth, 2015, Pharmacology and Therapeutics 150: 129-142. [cited by applicant]
Bock and Bermudez, 2021, FEBS Journal 288: 2513-2528. [cited by applicant]
Weis and Kobilka, 2018, Annual Review of Biochemistry 87: 897-919. [cited by applicant]
Inserra et al., 2020, Pharmacol. Rev 73: 202. [cited by applicant]
Haleem, D.j. Behav. Pharm. 2015, 26:45-58. [cited by applicant]
Amidfar, Meysam et al. Curr. Pharm. Des. 2018, 24:2541-2548. [cited by applicant]
McClure-Begley, T.D. et al. Nat. Rev. Drug Discov. 2022, 21:463-473. [cited by applicant]
Devroye, Celine et al. Pharmacol. Ther. 2018, 181:143-155. [cited by applicant]
Segelcke, Daniel et al. Cephalalgia 2017, 37:365-371. [cited by applicant]
Orsolini, Laura et al. Expert Rev. Neurother. 2016, 16:483-95. [cited by applicant]
Przegaliński, Edmund et al., 2023, Nutrients 15:1449. [cited by applicant]
Quintero-Villegas and Valdés-Ferrer, 2022, Molecular Medicine 28: 70. [cited by applicant]
Saggu et al., 2023, Molecular Psychiatry 28: 588-600. [cited by applicant]
Boiko et al., 2022, Neurochemical Research 47: 2909-2924. [cited by applicant]
Salatino-Olivera, Angelica et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2018, 177:211-231. [cited by applicant]
Outhred, Tim et al. Neurosci. Biobehav. Rev, 2013, 37:1786-800. [cited by applicant]
Polter and Li, 2010, Cell Signaling 22:1406-1412. [cited by applicant]
Finnin, B. and Morgan, T.M., 1999 J. Pharm. Sci, 88 (10), 955-958. [cited by applicant]
Y. Zou et al., Eur. J. Med. Chem., 138, 199-211 (2017). [cited by applicant]
K. N. Campbell et al., J. Org. Chem., 16, 1736 -1740 (1951). [cited by applicant]
Langin et al., Eur. J. Pharmacol. 167:95-104, 1989. [cited by applicant]
M. G. Cabiddu et al., Tetrahedron 59, 4383-4387 (2003). [cited by applicant]
Kozell et al., 2023, Journal of Pharmacology and Experimental Therapeutics 385:62-75. [cited by applicant]
Singh et al., 2023, Cell 186:2160-2175. [cited by applicant]
Islas and Scior, 2022, Molecules 27: 2977-2995. [cited by applicant]
Bulling et al., (2009, Journal of Biological Chemistry 287:18524-18534. [cited by applicant]
Zwartsen et al., 2017, Toxicology in Vitro 45:60-71. [cited by applicant]
Halberstadt and Geyer 2013, Psychopharmacology 227: 727-739. [cited by applicant]
Gonzalez-Maeso et al., 2007, Neuron 53:439-452. [cited by applicant]
Halberstadt et al., 2019, Journal of Psychopharmacology 33:406-414. [cited by applicant]
Fantegrossi et al., 2004, Psychopharmacology 173: 270-277. [cited by applicant]
Jaster et al., 2022, Psychopharmacology 239: 1665-1677. [cited by applicant]
Glennon, 1992, In: Boulton, Baker, Wu [Eds] Animal Models of Drug Addiction. Neuromethods 24, Humana Press. [cited by applicant]
Rickli et al., 2015, Neuropharmacology 99: 546. [cited by applicant]
Simmler et al., 2013, British J. Pharmacol. 168: 458. [cited by applicant]
Rickli et al., 2016, Eur. Neuropharm. 26: 1327. [cited by applicant]
Halberstadt, 2015, Behav. Brain Res. 277: 99. [cited by applicant]
Owens et al., 1997, Journal of Pharmacology and Experimental Therapeutics 283:1305-1322. [cited by applicant]
Rojas and Felder, 2016, Frontiers in Cellular Neuroscience 10:272. [cited by applicant]
Marcher-Rørsted et al., 2020, ACS Chem. Neurosci. 11: 1238. [cited by applicant]
Witt-Endersby and Dubocovich. Mol. Pharmacol. 50:166-174, 1996. [cited by applicant]
Pristupa et al., [Mol. Pharmacol. 45: 125-135, 1994. [cited by applicant]
Ly et al., 2018, Cell Reports 23:3170-3182. [cited by applicant]
Pittenger and Duman, 2008, Neuropsychopharmacology 33:88-109. [cited by applicant]
Braun et al. Centrally Active N-Substituted Analogs of 3,4-Methylenedioxyphenylisopropylamine (3,4-Methylenedioxyamphetamine), J Pharm Sci. 1980, 69(2), pp. 192-195. [cited by applicant]